Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric generalized myasthenia gravis study of intravenous nipocalimab
NL-OMON51698Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Primary endpoints: Effect on total serum IgG, Safety and tolerability and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON51698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51698.